Pure Global
NCT06119386

Quantum Molecular Resonance Electrotherapy in Severe Dry Eye Disease

Centro Oculistico Borroni·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Eye
Drug/Device/Intervention
Rexon-Eye
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Centro Oculistico Borroni
Location
Gallarate, Italy
Timeline & enrollment
Phase
N/A
Start date
Nov 03, 2022
End date
Feb 25, 2023
Enrollment
81 participants
Primary outcome

Ocular surface evaluation

Summary

To evaluate the efficacy and safety of Quantum Molecular Resonance (QMR) treatment in
 patients with severe dry eye disease (DED), as well as its effects on aqueous-deficient
 (ADDE), evaporative (EDE) and mixed (MDE) dry eye.

ICD-10 classifications
Ocular painAvulsion of eyeOther corneal deformitiesCorneal ulcerDry mouth, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06119386
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06119386 through Pure Global AI's free database. This phase not specified trial is sponsored by Centro Oculistico Borroni and is currently Completed. The study focuses on Dry Eye. Target enrollment is 81 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.